The role of macrophage migration inhibitory factor in obesity-associated type 2 diabetes in mice

Archives of Biological Sciences

Volumn 65, Issue 2, 2013, Pages 499-506

  Saksida, Tamara ^a   Stošić Grujičić, Stanislava ^a   Stojanović, Ivana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Inflammation; Macrophage migration inhibitory factor; Obesity; Type 2 diabetes

Indexed keywords

EID: 84876998295     PISSN: 03544664     EISSN: None     Source Type: Journal    
DOI: 10.2298/ABS1302499S     Document Type: Article

References (26)

1. Atsumi, T., Cho, Y.R., Leng, L., McDonald, C., Yu, T., Danton, C., Hong, E.G., Mitchell, R.A., Metz, C., Niwa, H., Takeuchi, J., Onodera, S., Umino, T., Yoshioka, N., Koike, T., Kim, J.K., and R. Bucala (2007). The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J. Immunol. 179, 5399-5406.
2. Calandra, T., Bernhagen, J., Mitchell, R.A., and R. Bucala (1994). The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895-1902.
3. Church, T.S., Willis, M.S., Priest, E.L., Lamonte, M.J., Earnest, C.P., Wilkinson, W.J., Wilson, D.A., and B.P. Giroir (2005). Obesity, macrophage migration inhibitory factor, and weight loss. Int. J. Obes. (Lond). 29, 675-681.
4. Cvetkovic, I., Al-Abed, Y., Miljkovic, D., Maksimovic-Ivanic, D., Roth, J., Bacher, M., Lan, H.Y., Nicoletti, F., and S. Stosic-Grujicic (2005). Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology, 146, 2942-2951.
5. Cvetkovic, I., and S. Stosic-Grujicic (2006). Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int. Immunopharmacol. 6, 1527-1534.
6. Dandona, P., Aljada, A., Ghanim, H., Mohanty, P., Tripathy, C., Hofmeyer, D., and A. Chaudhuri (2004). Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J. Clin. Endocrinol. Metab. 89, 5043-5047.
7. Donath, M.Y., and S.E. Shoelson (2011). Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107.
8. Ghanim, H., Aljada, A., Hofmeyer, D., Syed, T., Mohanty, P., and P. Dandona (2004). Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation, 110, 1564-1571.
9. Hirokawa, J., Sakaue, S., Tagami, S., Kawakami, Y., Sakai, M., Nishi, S., and J. Nishihira (1997). Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun. 235, 94-98.
10. Lambillotte, C., Gilon, P., and J.C. Henquin (1997). Direct glucocorticoid inhibition of insulin secretion - An in vitro study of dexamethasone effects in mouse islets. J. Clin. Invest. 99, 414-423.
11. Lumeng, C.N., and A.R. Saltiel (2011). Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111-2117.
12. Pascual, G., Fong, A.L., Ogawa, S., Gamliel, A., Li, A.C., Perissi, V., Rose, D.W., Willson, T.M., Rosenfeld, M.G., and C.K. Glass (2005). A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature, 437, 759-763.
13. Saksida, T., Stosic-Grujicic, S., Timotijevic, G., Sandler, S., and I. Stojanovic (2012). Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. Immunol. Cell Biol. 90, 688-698.
14. Serre-Beinier, V., Toso, C., Morel, P., Gonelle-Gispert, C., Veyrat-Durebex, C., Rohner-Jeanrenaud, F., Calandra, T., Roger, T., James, R.W., Montet, X., Bühler, L., Bosco, D., and T. Berney (2010). Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. J. Endocrinol. 206, 297-306.
15. Sheu, W.H., Chang, T.M., Lee, W.J., Ou, H.C., Wu, C.M., Tseng, L.N., Lang, H.F., Wu, C.S., Wan, C.J., and I.T. Lee (2008). Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring), 16, 1033-1038.
16. Skurk, T., Herder, C., Kräft, I., Müller-Scholze, S., Hauner, H., and H. Kolb (2005). Production and release of macrophage migration inhibitory factor from human adipocytes. Endocrinology, 146, 1006-1011.
17. Staab, C.A., and E. Maser (2010). 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J. Steroid Biochem. Mol. Biol. 119, 56-72.
18. Stosic-Grujicic, S., Stojanovic, I., and F. Nicoletti (2009). MIF in autoimmunity and novel therapeutic approaches. Autoimmun. Rev. 8, 244-249.
19. Stosic-Grujicic, S., Stojanovic, I., Maksimovic-Ivanic, D., Momcilovic, M., Popadic, D., Harhaji, L., Miljkovic, D., Metz, C., Mangano, K., Papaccio, G., Al-Abed, Y., and F. Nicoletti (2008). Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J. Cell Physiol. 215, 665-675.
20. Stumvoll, M., Goldstein, B.J., and T.W. Van Haeften (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365, 1333-1346.
21. Stumvoll, M., Goldstein, B.J., and T.W., Van Haeften (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365, 1333-1346.
22. Sumarac-Dumanovic, M., Stevanovic, D., Ljubic, A., Jorga, J., Simic, M., Stamenkovic-Pejkovic, D., Starcevic, V., Trajkovic, V., and D. Micic (2009). Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. (Lond). 33, 151-156.
23. Verschuren, L., Kooistra, T., Bernhagen, J., Voshol, P.J., Ouwens, D.M., van Erk, M., de Vries-van der Weij, J., Leng, L., van Bockel, J.H., van Dijk, K.W., Fingerle-Rowson, G., Bucala, R., and R. Kleemann (2009). MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ. Res. 105, 99-107.
24. Viardot, A., Lord, R.V., and K. Samaras (2010). The effects of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes and prediabetes. J. Clin. Endocrinol. Metab. 95, 2845-2850.
25. Waeber, G., Calandra, T., Roduit, R., Haefliger, J.A., Bonny, C., Thompson, N., Thorens, B., Temler, E., Meinhardt, A., Bacher, M., Metz, C.N., Nicod, P., and R. Bucala (1997). Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA, 94, 4782-4787.
26. Yabunaka, N., Nishihira, J., Mizue, Y., Tsuji, M., Kumagai, M., Ohtsuka, Y., Imamura, M., and M. Asaka (2000). Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care, 23, 256-258.